

State of Oklahoma SoonerCare

Nivestym[®] (Filgrastim-aafi), Neulasta[®] (Pegfilgrastim), Releuko[™] (Filgrastim-ayow), Stimufend[®] (Pegfilgrastim-fpgk), Udenyca[®] (Pegfilgrastim-cbqv), Nyvepria[™] (pegfilgrastim-pbbk) and Rolvedon[™] (Eflapegrastim-xnst) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
□Physician billing (HCPCS code:) □Pharmacy k	billing (NDC:)
Dose: Dosing Regimen:	Start	Date (or date of next dose):
Expected Treatment Duration/Number of Doses:		
Billing Provider Information		
Provider NPI: Provider Name:		
rovider Phone: Provider Fax:		x:
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone: Pre	escriber Fax:	Specialty:
Criteria		
Fulphila® (pegfilgrastim-jmdb filgrastim), Neupogen® (filgrastim) bmez): 2. For Nivestym® (Filgrastim-aafi) and information: A. Diagnosis:	o), Fylnetra [®] (pegfilgrastin astim), Zarxio [®] (filgrastin d Releuko™ (Filgrastim ecific, clinically significan	t reason why the member cannot use im-pbbk 6mg/0.6ml), Granix® (tbo-m-sndz), or Ziextenzo® (pegfilgrastim-m-ayow), please indicate the diagnosis t reason why the member cannot use arxio® (filgrastim-sndz):
Additional Information:		
Prescriber Signature: I certify that the indicated treatment is the best of my knowledge.	s medically necessary a	Date:and all information is true and correct to

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 208 7/19/2023